Hims House

In episode 23, Jonathan Stern and Patrick Lester (Bayside) welcome Andrew Dudum, the founder and CEO of Hims & Hers, for the most anticipated conversation in Hims House history. They discuss the growth of Hims' core business, the evolving landscape of GLP-1 medications, the company's dedication to consumer rights, and how Andrew thinks about navigating regulatory challenges. Andrew also shares insights into why Hims is positioned to succeed even during tough economic conditions, and he draws comparisons between Hims, Netflix, Amazon, and Uber. The episode concludes on a personal note, with Andrew recounting the story behind his family’s donut shop, George’s Donuts and Merriment, named in honor of his grandfather.

00:00 Introduction

00:57 Growth of the "Core" Business

04:25 GLP-1s

15:23 Macroeconomic Uncertainty and Business Strategy

18:00 Engaging with the Trump Administration

21:47 Comparing Hims to Netflix, Amazon, Uber, and more

29:46 Personal Story: George's Donuts & Merriment

In this emergency episode of Hims House, the crew covers the FDA's surprise resolution of the semaglutide shortage. They discuss its immediate market impact, including significant stock price movements. Bayside provides a detailed analysis of the implications for short-term and long-term traders. The conversation then shifts to HIMS' two recent acquisitions—a peptide manufacturing facility and an at-home testing lab—and their effects on the company's future. As they wrap up, the team outlines critical points to watch in the upcoming earnings report, especially guidance for 2025 and strategic plans for patient care in light of the new developments.

00:00 Semiglutide Shortage Resolved According to FDA

01:33 Short-term vs Long-term Investment Perspectives

04:05 Institutional Ownership and Long-term Implications

04:48 Future Projections and Speculations

06:01 FDA Policies and GLP-1 Sales Impact

22:02 Acquisitions and Strategic Moves

32:00 Earnings Expectations and Guidance

42:18 Conclusion

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H discuss the recent Super Bowl ad for Hims and its widespread media attention. They explore the varied public reception of the ad, its impact on healthcare perceptions, and the spike in app rankings. The episode delves into the growth trajectories of the Hims and Hers brands and scrutinizes the ramifications of the hot CPI report on the financial market. The panel also addresses the stock's peak performance amid high short interest and institutional ownership dynamics, providing a detailed analysis of market reactions and future expectations.

00:20 Superbowl Ad Impact

03:20 Hers App Success

10:02 CPI and Market Analysis

19:57 Short Interest and Market Dynamics

27:59 Upcoming Catalysts

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H discuss HIMS' recent performance and the unveiling of their upcoming minute-long Super Bowl ad. The discussion delves into the strategic rationale behind this move, its potential to create strong brand awareness, and its alignment with the broader goal of establishing a 'brand moat.' The trio then addresses the record-high short interest in HIMS, now exceeding 30%, and analyzes the dynamics that could lead to a short squeeze. The episode concludes with speculation about a potential new product—testosterone therapy—and its implications for HIMS' expanding multi-product portfolio.

00:44 Super Bowl Ad

01:04 Brand Awareness and Marketing Strategy

08:06 Political Messaging in Advertising

19:10 Record High Short Interest

26:26 Understanding Short Squeeze Potential

29:04 Analyzing Short Interest and Market Perception

30:50 Historical Context of Shorted Stocks

34:41 GameStop Comparison and Stock Value Fundamentals

39:38 Potential New Product: Testosterone

47:22 Conclusion and Final Thoughts

NOTE: Analysis and opinions expressed by Jack are his and his alone, and are not to be interpreted as a reflection of opinions by his current or former employers.

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H are joined by a special guest, Jack, a former sell-side analyst. Jack provides a comprehensive analysis of the Hims & Hers business, rooted in his years of following the company since 2022. The discussion kicks off with an overview of the financial industry, contrasting the roles of sell-side and buy-side analysts. Jack elaborates on his interest in following HIMS, emphasizing the company's successful transition from a patient-centric to a consumer-centric healthcare provider. The episode highlights a recent Bank of America report predicting a revenue shortfall for HIMS, exploring credit card data intricacies and deferred revenue impacts. Finally, the conversation delves into HIMS' long-term prospects, potential regulatory hurdles, international viability, and their unique market position.

00:00 Introduction

00:42 Understanding the Sell Side vs. Buy Side

02:17 Jack's Interest in HIMS

03:46 Bank of America Report Analysis

05:42 Deferred Revenue and Credit Card Data

11:40 Impact of Amazon on HIMS

18:32 Consumer vs. Patient Behavior

22:07 Cash Pay Option in Healthcare

26:22 HIMS' Long-Term Vision and International Expansion

31:35 Debating the Future of Diabetes Care

32:41 Challenges in High Acuity Care

34:04 Teladoc and Livongo: A Case Study

36:07 Impact of COVID on Digital Health

40:21 Consumer vs. Patient Psychology

47:01 The Future of Weight Loss and Diabetes Treatment

52:08 2025 Predictions and Key Indicators

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H are joined by Bayside, a professional lobbyist in Washington D.C., to discuss the upcoming Trump administration and its potential impact on Hims, particularly concerning the semaglutide shortage. Bayside provides a detailed analysis of the semaglutide and tirzepatide shortages, FDA decisions, and political landscape affecting HIMS investors. The discussion expands to consider the potential influence of Elon Musk and Trump on healthcare policy, Greenland acquisition implications, and the roles of RFK and Marty Makary in shaping future healthcare regulations. Dr. H offers insights into the medical necessity of compounded medications and telehealth implications.

00:00 Introduction

01:05 Semaglutide Shortage Analysis

02:48 FDA Decision Timeline

06:44 Impact of New Administration

10:34 HIMS Sales Strategy Post-Shortage

14:29 Legal and Medical Perspectives

28:57 Custom Dosage and Medical Necessity

29:46 Corporate Practice of Medicine

30:28 Patent System and Compounding Controversy

31:30 Chevron Doctrine and Legal Battles

32:08 Impact on HIMS Stock and Lawsuits

34:59 Future of Compounding and Revenue

36:58 Elon Musk, Trump, and GLP-1 Pricing

42:02 Greenland and Geopolitical Leverage

46:46 RFK and Marty McCary's Impact on Healthcare

57:46 Conclusion and Future Topics

Full access to our HIMS Data Dashboard + research library is $10/mo ($100/yr). Join 1,400 other HIMS investors today!

In episode 17 of Hims House, Jonathan Stern, Louis Stevens, and Dr. H reflect on the significant milestones and performance of Hims & Hers in 2024, marking it as a watershed year for the company. They discuss the company's financial growth, product launches, strategic hires, and customer base expansion. The trio also dissects the challenges faced, including legal battles and market skepticism. The conversation highlights Hims' expansion into weight loss treatments, branding strategies, and the implications of free cash flow and customer acquisition costs. Looking ahead, they share their predictions for 2025, focusing on growth opportunities and potential stock performance.

00:00 New Year Greetings

00:29 2024 Year in Review: Key Highlights

00:51 HIMS Company History and Growth

02:19 Financial Performance and Market Dynamics

07:21 Marketing and Brand Recognition

08:18 New Products and Strategic Hires

11:02 Surprises and Strategic Decisions

15:24 Stock Market Performance and Sentiment

20:16 Biggest Wins of 2024

24:49 Subscriber Growth and Acquisitions

29:21 Looking Ahead to 2025

34:03 Predictions and Final Thoughts

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H are joined by a special guest, Bayside, a professional lobbyist who works in Washington D.C. They discuss the recent FDA announcement about the tirzepatide shortage resolution and its implications on HIMS. Bayside shares insights from his 12-page research report, which accurately predicted this outcome, and provides a detailed analysis of FDA politics, the pharmaceutical industry, and future expectations for GLP-1 compounds like semaglutide. The episode also explores potential partnerships, legal challenges, and the role of personalized medicine in the context of compounding.

00:00 Introduction

00:31 FDA Announcement and Market Reaction

00:53 Bayside's Research and Predictions

04:27 Political and Legal Implications

08:15 Semaglutide Shortage and Market Impact

19:23 Court Filings and Hims Supply Tracker

20:43 Reactions and Future Outlook

21:22 FDA Regulations and Discretion

22:35 Elon Musk's Influence and Motivations

23:31 Compounding and Personalized Medicine

26:01 Legal and Medical Perspectives on Dosage Variances

31:01 Hims and the Pharmaceutical Industry

36:25 Future of GLP-1 Drugs and Market Dynamics

41:35 Speculations and Future Partnerships

In episode 15 of Hims House, Jonathan Stern, Louis Stevens, and Dr. H discuss recent news about Meta restricting data access for healthcare companies like Hims and the implications for Hims’ marketing strategies. They examine the parallels between Meta's past challenges with Apple's privacy policies and how Hims might navigate similar issues, ultimately predicting that Hims’ vertically integrated platform will help it thrive. The episode also covers new partnerships in the telehealth industry, such as Ro partnering with pharmaceutical giant Lilly, and debates the American Diabetes Association's stance against compounded GLP-1 drugs, highlighting concerns around safety and efficacy while affirming Hims’ robust approach to patient care.

00:00 Introduction

01:46 Why Meta’s Data Restriction Might Be Bullish

05:58 Meta's Transition from Bearish to Bullish

14:35 Ro and Lilly Partnership Announcement

27:02 American Diabetes Association Stance on Compounded GLP-1s

44:33 Primary Care and Telemedicine Expertise

Subscribe to Hims House!

Website: himshouse.substack.com

Twitter/X: x.com/himshouse

Discord: discord.gg/tJqGgVhkEt

Follow us on Twitter/X:

Jonathan Stern - x.com/jonathanrstern

Louis Stevens - x.com/LA_stevens_

Dr. H - x.com/stayathomedoc

In Episode 14 of Hims House, host Jonathan Stern is joined by Louis Stevens and Dr. H to discuss the FDA's delayed decision on terzepatide shortages, its implications for Hims, and how it may reflect on semaglutide. They dive into the importance of anchoring to the long-term vision of Hims amid market volatility and debate the FDA’s growing acknowledgment of the medication shortage. The team also explores the newly launched meal replacement bars and shakes by Hims and their potential impact on the business. They further discuss the market reactions, the diverse weight loss product range, and the integral understanding needed for sustainable growth in the telehealth and wellness space.

00:00 Introduction and Episode Overview

00:30 FDA Decision on Terzapatide Shortage

01:04 Impact on Hims and Market Reactions

01:35 Review of FDA's Actions and Industry Reactions

05:31 Discussion on Compounded Medications

11:34 Remembering the Long-Term Thesis for Hims

28:58 New Product Launch: Meal Replacement Bars and Shakes